| Value | ₹1.48 Cr |
|---|
BSE filing, NSE: ERIS. Summary written from the filing by ALFA Finder's alert engine.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,163.60
- Market cap
- ₹16,144 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 22.8×Sector 48.7×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Q2 FY27 Results: Net Profit ₹187.1 Cr, Up 39.1% YoY
Eris Lifesciences Ltd reported revenue from operations of ₹892.4 Cr (+12.6% YoY) and net profit of ₹187.1 Cr (+39.1% YoY) for Q2 FY27.
- Key figure
- Net profit ₹187.1 Cr · +39.1% YoY
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Eris Lifesciences Management Change
Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.
Other employee stock options announcements
All →Cholamandalam Investment & Finance Company Employee Stock Options
Cholamandalam Investment and Finance allotted 1,20,202 equity shares to employees upon the exercise of stock options. The company will now seek listing for these shares.
Mahindra & Mahindra Employee Stock Options
Mahindra & Mahindra transferred equity shares from its ESOP Trust to employees upon exercise of stock options. This is a routine employee benefit disclosure.
JSW Energy Employee Stock Options
JSW Energy's employee welfare trust transferred 10,044 shares to employees after ESOP option exercises. The off-market transfer was valued at about Rs 0.01 Crore.
- Value
- ₹0.01 Cr
Indegene Employee Stock Options
Indegene Limited allotted 52,194 equity shares under its ESOP schemes, raising paid-up capital to Rs.48.21 Crore. No cash fund raise is involved, so no event value applies.
Raymond Employee Stock Options
Raymond allotted 1,56,784 equity shares to its ESOP Trust under the Raymond Employees Stock Option Plan 2023. Paid-up capital rose to Rs. 66,73,05,150.
Alivus Life Sciences Employee Stock Options
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.